Back to Search
Start Over
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
- Source :
-
European Journal of Cancer . Mar2020, Vol. 127, p173-182. 10p. - Publication Year :
- 2020
-
Abstract
- The present study (VINGEM) is the first randomised trial comparing vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with advanced urothelial carcinoma (aUC) ineligible for treatment with cisplatin. Patients with aUC, creatinine clearance 30–60 ml/min, performance status ≤1 and no prior chemotherapy for metastatic disease were randomised to the experimental arm (vinflunine 280 or 250 mg/m2 day 1, gemcitabine 1000 mg/m2 days 1 and 8, q21 days) or the control arm (carboplatin AUC 4.5 day 1, gemcitabine 1000 mg/m2 days 1 and 8, q21 days). Primary end-point was progression-free survival (PFS). Sixty-two patients were randomised; a total of 59 patients were treated (29 VG, 30 CG). There was no significant difference in PFS between the treatment arms: median 6.2 months for VG versus 6.3 months for CG (hazard ratio [HR]: 0.75, 95% confidence interval [CI]: 0.44–1.28; P = 0.293). Median overall survival was 12.5 months for VG versus 10.6 months for CG. The overall response rate (ORR) was higher in the VG arm than in the CG arm (63% versus 40%) but was not statistically significant in the intention-to-treat analysis. Furthermore, VG showed a high complete response (CR) rate, 22% versus 3% in CG. In the per-protocol group, both ORR and CR were significantly higher for VG than for CG. The most common adverse events (AEs) were fatigue, haematological toxicities, gastrointestinal disorders and nausea/vomiting. Common grade III/IV AEs were neutropenia (VG 62%, CG 43%), thrombocytopenia (VG 7%, CG 37%) and febrile neutropenia (VG 31%, CG 7%). The combination of VG did not improve PFS compared with standard treatment with CG in patients unfit for cisplatin due to renal impairment. The response rate of VG indicates, however, an active regimen and warrants further studies. NCT02665039. • This was the first trial comparing vinflunine/gemcitabine (VG) vs carboplatin/gemcitabine (CG) in advanced urothelial cancer. • VG showed clinically meaningful efficacy with high overall and complete response rates. • VG did not improve median progression-free survival but was comparable with CG. • VG showed high incidence of neutropenia but with overall feasible side-effects. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ANTIMETABOLITES
*ANTINEOPLASTIC agents
*CISPLATIN
*CONFIDENCE intervals
*DRUG side effects
*FEBRILE neutropenia
*GASTROINTESTINAL diseases
*NAUSEA
*STATISTICAL sampling
*THROMBOCYTOPENIA
*VOMITING
*RANDOMIZED controlled trials
*TREATMENT effectiveness
*CARBOPLATIN
*CANCER fatigue
BLADDER tumors
Subjects
Details
- Language :
- English
- ISSN :
- 09598049
- Volume :
- 127
- Database :
- Academic Search Index
- Journal :
- European Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 141730535
- Full Text :
- https://doi.org/10.1016/j.ejca.2019.08.033